摘要
炎症在肿瘤的发生及发展中起着重要的作用,淋巴细胞和单核细胞是炎症反应的关键免疫细胞,可以反映机体免疫状态。近年来,越来越多的临床研究显示肿瘤患者治疗前外周血淋巴细胞/单核细胞比值(Lymphocyte-to-monocyte ratio,LMR)可能对评价患者的预后存在一定的价值。LMR对于头颈部肿瘤、食管癌、乳腺癌、卵巢癌、肺癌、胃癌、结直肠癌等恶性肿瘤预后价值已经得到证实。本文就LMR在恶性肿瘤患者对评价预后的价值方面做一综述。
Inflammation has a critical role in the pathogenesis and progression of cancer, lymphocyte and monocyte play an important role in inflammatory reaction,reflecting body immune status. In recent years,more and more clinical studies have shown that pretreatment of lymphocyte - to - monocyte ratio（ LMR） in the patients with malignant tumor may have a certain value in evaluating the prognosis of cancer patients such as nasopharyngeal cancer,esophageal cancer, breast cancer, ovarian cancer, lung cancer, gastric cancer, colorectal cancer, etc. This article reviews the latest research progress on the value of LMR in the evaluation of the prognosis of the patients with malignant tumor.
出处
《实用肿瘤学杂志》
CAS
2017年第2期188-192,共5页
Practical Oncology Journal
关键词
淋巴细胞/单核细胞比值
肿瘤
预后
炎性因子
Lymphocyte - to - monocyte ratio
Tumors
Prognosis
Inflammatory factor
